Naushad Ahmad Khan1, Harish Saini2, Govind Mawari3, Suman Kumar4, Harmanjit Singh Hira5, Mradul Kumar Daga6. 1. Research Associate, Department of Medicine, Maulana Azad Medical College , New Delhi, India . 2. Senior Resident, Department of Medicine, Maulana Azad Medical College , New Delhi, India . 3. Research Co-ordinator, Department of Medicine, Maulana Azad Medical College , New Delhi, India . 4. Research Officer, Department of Microbiology, Maulana Azad Medical College , New Delhi, India . 5. Director Professor, Department of Pulmonary Medicine, Maulana Azad Medical College , New Delhi, India . 6. Director Professor, Department of Medicine, Maulana Azad Medical College , New Delhi, India .
Abstract
INTRODUCTION: Preliminary studies have established the elevated plasma total Homocysteine (tHcy) levels as a risk factor for Chronic Obstructive Pulmonary Disease (COPD). However, studies describing plasma tHcy levels and their relationship to folic acid supplementation and Forced Expiratory Volume in 1 Second (FEV1) status in COPD patients are still lacking. AIM: We investigated the role of hyperhomocysteinemia in COPD and then prospectively examined the relationship between plasma tHcy concentration and effect of folic acid supplementation on FEV1 status in COPD patients. MATERIALS AND METHODS: This was a prospective case-control study with 50 clinically stable patients of COPD attending the chest clinic of the hospital and 30 healthy controls. The study was done at Maulana Azad Medical College and associated Lok Nayak Hospital, New Delhi, India, from August 2011 to February 2013. Plasma levels of Hcy were measured by Enzyme Linked Immuno-Sorbent Assay (ELISA) method. All the subjects were given folic acid therapy (5mg daily) for six weeks duration and were followed up. Repeat plasma Hcy and FEV1 were measured after six weeks. RESULTS: COPD patients had higher baseline plasma tHcy concentration than controls (Mean: 27.42±23.89μmol/L, versus 15.21±15.71μmol/L, p<0.001) and COPD was associated with higher tHcy concentrations also after adjusting for smoking, and age. The mean BMI of the patients was 21.36±4.26kg/m2. The mean Hcy values decreased from 27.42±23.89μmol/L to 15.2±15.71μmol/L (p-value=0.001) after six weeks of folic acid supplementation. However, no significant change was observed in FEV1 upon folic acid supplementation (FEV1=1.14±0.60 and 1.08±0.56 respectively; p-value=0.654). A significant correlation was observed between BMI and Hcy and also between plasma Hcy levels at the baseline and after six weeks of folic acid supplementation (r=0.283, p=0.04 and r=0.340, p=0.02, respectively) and (r=0.840, p=0.001). CONCLUSION: COPD patients seem to have a poor folic acid status and as a consequence high tHcy. Also, folic acid supplementation has shown decreased plasma tHcy concentrations, but not necessarily significant change in FEV1.
INTRODUCTION: Preliminary studies have established the elevated plasma total Homocysteine (tHcy) levels as a risk factor for Chronic Obstructive Pulmonary Disease (COPD). However, studies describing plasma tHcy levels and their relationship to folic acid supplementation and Forced Expiratory Volume in 1 Second (FEV1) status in COPDpatients are still lacking. AIM: We investigated the role of hyperhomocysteinemia in COPD and then prospectively examined the relationship between plasma tHcy concentration and effect of folic acid supplementation on FEV1 status in COPDpatients. MATERIALS AND METHODS: This was a prospective case-control study with 50 clinically stable patients of COPD attending the chest clinic of the hospital and 30 healthy controls. The study was done at Maulana Azad Medical College and associated Lok Nayak Hospital, New Delhi, India, from August 2011 to February 2013. Plasma levels of Hcy were measured by Enzyme Linked Immuno-Sorbent Assay (ELISA) method. All the subjects were given folic acid therapy (5mg daily) for six weeks duration and were followed up. Repeat plasma Hcy and FEV1 were measured after six weeks. RESULTS:COPDpatients had higher baseline plasma tHcy concentration than controls (Mean: 27.42±23.89μmol/L, versus 15.21±15.71μmol/L, p<0.001) and COPD was associated with higher tHcy concentrations also after adjusting for smoking, and age. The mean BMI of the patients was 21.36±4.26kg/m2. The mean Hcy values decreased from 27.42±23.89μmol/L to 15.2±15.71μmol/L (p-value=0.001) after six weeks of folic acid supplementation. However, no significant change was observed in FEV1 upon folic acid supplementation (FEV1=1.14±0.60 and 1.08±0.56 respectively; p-value=0.654). A significant correlation was observed between BMI and Hcy and also between plasma Hcy levels at the baseline and after six weeks of folic acid supplementation (r=0.283, p=0.04 and r=0.340, p=0.02, respectively) and (r=0.840, p=0.001). CONCLUSION:COPDpatients seem to have a poor folic acid status and as a consequence high tHcy. Also, folic acid supplementation has shown decreased plasma tHcy concentrations, but not necessarily significant change in FEV1.
Authors: Robert Clarke; Helga Refsum; Jacqueline Birks; John Grimley Evans; Carole Johnston; Paul Sherliker; Per M Ueland; Joern Schneede; Joseph McPartlin; Ebba Nexo; John M Scott Journal: Am J Clin Nutr Date: 2003-05 Impact factor: 7.045
Authors: Eva Lonn; Salim Yusuf; Malcolm J Arnold; Patrick Sheridan; Janice Pogue; Mary Micks; Matthew J McQueen; Jeffrey Probstfield; George Fodor; Claes Held; Jacques Genest Journal: N Engl J Med Date: 2006-03-12 Impact factor: 91.245
Authors: José Luis Izquierdo; Arturo Martínez; Elizabet Guzmán; Pilar de Lucas; José Miguel Rodríguez Journal: Int J Chron Obstruct Pulmon Dis Date: 2010-11-08
Authors: Angelo Zinellu; Elisabetta Zinellu; Maria Carmina Pau; Alessandro G Fois; Sabrina Mellino; Barbara Piras; Valentina Scano; Sara S Fois; Arduino A Mangoni; Ciriaco Carru; Pietro Pirina Journal: Clin Exp Med Date: 2022-05-05 Impact factor: 5.057